A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

To join this study, you must have recently been diagnosed with multiple myeloma. It's important that your doctor has decided that a high-dose chemotherapy treatment with a stem cell transplant isn't the right first step for you, either because of your age or other health issues, or if you're choosing to delay that treatment.

You also need to be generally well enough to take part. This means your daily activities shouldn't be too limited by your health. Both men and women aged 18 and over can participate. If you're a woman, you must not be pregnant, breastfeeding, or planning to become pregnant during the study and for six months afterwards. If you're a man, you must not plan to father a child during the study and for 100 days after your last treatment dose.

There are also some reasons why you might not be able to join. For example, if you've already had treatment for multiple myeloma (other than a very short course of steroids), or if you've had certain medical events like a stroke recently. Also, if you have known allergies to any of the study medications, or certain severe health conditions, you wouldn't be able to take part.

If you decide to take part in this study, you'll be assigned to one of three treatment groups. This decision is made randomly, like flipping a coin. You will receive either Teclistamab with Daratumumab and Lenalidomide, Talquetamab with Daratumumab and Lenalidomide, or Daratumumab, Lenalidomide, and Dexamethasone. You will receive regular doses of these medications, which will involve visits to the clinic for treatments and check-ups.

Throughout the study, you will have regular medical appointments, blood tests, and other examinations to monitor your health, how the treatment is working, and to check for any side effects. This will help the doctors understand the effects of the treatments. The total length of the study for each participant will vary, but it involves ongoing treatment cycles followed by a follow-up period to monitor your long-term health. You will be given a detailed schedule by the study team.